Absorb Bioresorbable Vascular Scaffold System
VASCULAR
hamburger
product photo

having nothing can mean everything

BODY OF EVIDENCE:

Large Clinical Program and Real World Use

Absorb Bioresorbable Scaffold clinical program and real world use

Absorb Bioresorbable Scaffold clinical evidence

For more information, visit www.absorb.com


*Small platinum markers near scaffold edges remain.

**Absorb improves coronary luminal diameter, restores blood flow and enables movement of the treated vessel. Source: Absorb GT1 IFU

1. Serruys, P.W.,et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis, 5-Year Follow-Up, J Am Coll Cardiol. 2016; DOI: 10.1016/j.jacc.2015.11.060
2. Yamaji, K., et al. Very Long-Term Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation, Circ Cardiovasc Interv. 2010: DOI; 10.1161/CIRCINTERVENTIONS.110.958249
3. Hernandez F. REPARA. EuroPCR 2015.
4. Hamm C. GABI-R Presentation. EuroPCR 2015.
5. Serruys PW. TROFI II. ESC 2015.
6. De La Torre Hernandez JM. ESTROFA BVS. EuroPCR 2015.
7. Kereiakes DJ. ABSORB III 1-year. TCT 2015.
8. Kimura T et al. Euro Heart J. Advanced access published 1 Sep 2015. doi:10.1093/eurheartj/ehv435.
9. Gao RL. ABSORB China 1-year Presentation. TCT 2015.
10. Seth A. ABSORB FIRST, TCT 2015.
11. Capranzano, P., GHOST EU, EuroPCR 2015.
12. Chevalier B. ABSORB II 2-year. TCT 2015.
13. Schwenke, ASSURE, TCT 2015.
14. Bartorelli A. ABSORB EXTEND. TCT 2015
15. Serruys PW et al. ABSORB Cohort B 5-Year. TCT 2015.
16. Sales data through May 2016, 1.2 units/patient, Data on file at Abbott Vascular
17. Clinical Studies through 2016.
18. AIDA, EVERBIO, ABSORB II, ABSORB III, ABSORB IV, ABSORB Japan, ABSORB China, COMPARE Absorb, Trofi II, Prospect II, ISAR Absorb, PREVENT
19. ABSORB First, ABSORB Extend, Gabi–R, REPARA, UK registry, IT-Disappears, France ABSORB, FEAST.RU, RAI Registry, SMART REWARD, ABSORB Australia, BVS EXPAND, ASSURE, PABLOS, Absorb CTO, Prague – 19, GHOST Ferrarotto, POLAR ACS, GHOST EU. Cohort B.

The Absorb GT1 (Absorb) BVS is a cutting-edge advance in percutaneous coronary intervention (PCI). This breakthrough technology repairs and revascularizes like the best-in-class XIENCE drug-eluting stent. Unlike a drug-eluting stent that is a permanent metallic implant, Absorb is naturally resorbed in the body, leaving nothing* behind.

The Absorb bioresorbable technology offers more than a device-free artery. Absorb also restores** vasomotor function and pulsatility1, allowing the artery to more naturally regulate blood flow.

ALLOWS RESTORATION THROUGH MECHANICAL CONDITIONING AND BIORESORPTION

  • Drug elution timed like XIENCE to match restenosis cascade
  • Loss of mechanical support permits mechanical conditioning of tissue to promote healing2
  • Full mass loss at approximately 3 years to enable neomedia formation and natural function3

Absorb Bioresorbable Scaffold Allows Restoration Through Mechanical Conditioning and Bioresorption

ABSORB GT1 PRODUCT DESIGN ELEMENTS

Absorb Bioresorbable Scaffold product design elements

For more information, visit www.absorb.com

1. Serruys, P.W.,et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis, 5-Year Follow-Up, J Am Coll Cardiol. 2016; DOI: 10.1016/j.jacc.2015.11.060
2. Wijns W, et al. CCI. 2008; Circ Cardiovasc Interv 2008;1;193-200. Wijns, W, et al. JACC. June. 2008; doi:10.1016/j.jacc.2007.12.059.
3. Courtesy of Dr. R.J. van Geuns, Rotterdam, The Netherlands; De Bruyne, B. ABSORB Cohort B 5-year, TCT 2014.
* Small platinum markers at scaffold edge remain for fluoroscopic landmarking.
**Absorb improves coronary luminal diameter, restores blood flow and enables movement of the treated vessel. Source: Absorb GT1 IFU
† Improved as compared to Absorb BVS. Tests performed by and data on file at Abbott Vascular.
+ XIENCE family of products: XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine.

absorb repair restore renew

ABSORB III MET PRIMARY ENDPOINT FOR FDA APPROVAL1

In the ABSORB III pivotal trial, Absorb was non-inferior to Xience for the primary endpoint of TLF at 1 year (non-inferiority p value of 0.0007).

Absorb III Trial: Absorb vs. Xience

COMPARABLE TO XIENCE IN ABSORB III1

Absorb III Trial: Absorb comparable to Xience

Absorb III Trial: Absorb vs. Xience Scaffold Thrombosis Analysis

EARLY SIGNALS OF REDUCED LONG-TERM EVENTS WITH ABSORB

Absorb III Trial: Reduced long-term events with Absorb

Absorb Serial IVUS results

Absorb safety results

For more information, visit www.absorb.com

1. Kereiakes, D,. ABSORB III TCT 2015
2. Serruys, P.W.,et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis, 5-Year Follow-Up, J Am Coll Cardiol. 2016; DOI: 10.1016/j.jacc.2015.11.060
3. Gada H et al. SPIRIT III 5-year. JACC Cardiovasc Interv. 2013;6:1263-1266.
4. Bartorelli A. ABSORB EXTEND. TCT 2015
5. Chevalier B., ABSORB II 2-Year, TCT 2015.
6. See Absorb GT1™ FDA Panel, March 2016. http://www.fda.gov/AdvisoryCommittees/default

absorb repair restore renew

 

PSP TECHNIQUE SUPPORTS BRS THERAPY ADVANCEMENT

  • Globally acknowledged appropriate implantation technique has three steps

Absorb implantation technique 3 steps

absorb repair restore renew

ORDERING INFORMATION

Absorb Scaffold ordering information

PRODUCT INFO

Our online product catalogs provide the very latest information available, right at your fingertips. Download catalogs by product family in PDF format, or view the entire Abbott Vascular inventory in Excel. Product barcodes enable direct scanning for easy reordering.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

rxAbsorb GT1 Bioresorbable Vascular Scaffold System

INDICATIONS

The Absorb GT1 Bioresorbable Vascular Scaffold (BVS) is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.

CONTRAINDICATIONS

The Absorb GT1 BVS System is contraindicated for use in:

  • Patients who cannot tolerate, including allergy or hypersensitivity to, procedural anticoagulation or the post-procedural antiplatelet regimen.
  • Patients with hypersensitivity or contraindication to everolimus or structurally-related compounds, or known hypersensitivity to scaffold components (poly(L-lactide), poly(D,L-lactide), platinum) or with contrast sensitivity.

WARNINGS
 

  • For single use only. Do not resterilize or reuse. Note the product "Use by" date on the package.
  • Careful assessment of the target lesion reference vessel diameter and selection of the appropriate scaffold diameter relative to the target lesion reference vessel diameter are required to minimize potential damage to the scaffold during post-dilatation and to ensure adequate scaffold apposition and an appropriate post-implantation minimum lumen diameter.
  • In small vessels (visually assessed reference vessel diameter ≤ 2.75 mm), on-line QCA or intravascular imaging with intravascular ultrasound or optical coherence tomography is strongly recommended to accurately measure and confirm appropriate vessel sizing (reference vessel diameter ≥ 2.5 mm). (See Section 8.1.6 – Implantation of Absorb in Small Coronary Arteries (Post Hoc Analysis)).
  • If quantitative imaging determines a vessel size < 2.5 mm, do not implant the Absorb GT1 BVS. Implantation of the device in vessels < 2.5 mm may lead to an increased risk of adverse events such as myocardial infarction and scaffold thrombosis.
  • Adequate lesion preparation prior to scaffold implantation is required to ensure safe delivery of the scaffold across the target lesion. It is not recommended to treat patients having a lesion that prevents complete inflation of an angioplasty balloon. It is strongly recommended to achieve a residual stenosis between 20% and 40% after pre-dilatation to enable successful delivery and full expansion of the scaffold.
  • Ensure the scaffold is not post-dilated beyond the allowable expansion limits (see Absorb GT1 IFU Section 12.7 - Clinician Use Information, Further Expansion of the Deployed Scaffold).
  • Antiplatelet therapy should be administered post-procedure (see Absorb GT1 IFU Section 9.1 - Patient Selection and Treatment, Individualization of Treatment).
  • This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy.
  • Judicious selection of patients is necessary, since the use of this device carries the associated risk of scaffold thrombosis, vascular complications, and / or bleeding events.

PRECAUTIONS
 

  • Implantation of the scaffold should be performed only by physicians who have received appropriate training.
  • Do not exceed the Rated Burst Pressure (RBP) as indicated on the product label.
  • Post-dilatation is strongly recommended for optimal scaffold apposition. When performed, post-dilatation should be at high pressure (> 16 atm) with a noncompliant balloon.
  • Care must be taken to properly size the scaffold to ensure that the scaffold is in full contact with the arterial wall upon deflation of the balloon. All efforts should be made to ensure that the scaffold is not under dilated. Refer to Absorb GT1 IFU Section 12.7 - Clinical Use Information, Further Expansion of the Deployed Scaffold.
  • Balloon dilatation of any cells of a deployed Absorb GT1 BVS may cause scaffold damage. Avoid scaffolding across any side branches ≥ 2.0 mm in diameter. Placement of a scaffold has the potential to compromise side branch patency.
  • It is not recommended to treat patients having a lesion with excessive tortuosity proximal to or within the lesion.
  • Non-clinical testing has demonstrated the Absorb GT1 BVS is MR Conditional. A patient with this device can be safely scanned in all MR environments 3T or less.
  • The safety and effectiveness of the Absorb GT1 BVS have not been established for subject populations with the following characteristics:
    • Coronary artery reference vessel diameters < 2.5 mm or > 3.75 mm
    • Lesion lengths > 24 mm
    • Lesions located in arterial or saphenous vein grafts
    • Lesions located in unprotected left main artery
    • Ostial lesions
    • Lesions located at a bifurcation
    • Previously stented lesions
    • Moderate to severe calcification
    • Chronic total occlusion or poor flow (< TIMI 1) distal to the identified lesions
    • Three-vessel disease
    • Unresolved thrombus at the lesion site or anywhere in the vessel to be treated
    • Excessive tortuosity proximal to or within the lesion
    • Recent acute myocardial infarction (AMI)

POTENTIAL ADVERSE EVENTS

Adverse events that may be associated with PCI, treatment procedures and the use of a coronary scaffold in native coronary arteries include the following, but are not limited to:

  • Allergic reaction or hypersensitivity to latex, contrast agent, anesthesia, device materials (platinum, or polymer [poly(L-lactide) (PLLA), polymer poly(D,L-lactide) (PDLLA)]), and drug reactions to everolimus, anticoagulation, or antiplatelet drugs, Vascular access complications which may require transfusion or vessel repair, including: Catheter site reactions, Bleeding (ecchymosis, oozing, hematoma, hemorrhage, retroperitoneal hemorrhage), Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture, Embolism (air, tissue, plaque, thrombotic material or device), Peripheral nerve injury, Peripheral ischemia, Coronary artery complications which may require additional intervention, including: Total occlusion or abrupt closure, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture, Tissue prolapse / plaque shift, Embolism (air, tissue, plaque, thrombotic material or device), Coronary or scaffold thrombosis (acute, subacute, late, very late), Stenosis or restenosis, Pericardial complications which may require additional intervention, including: Cardiac tamponade, Pericardial effusion, Pericarditis, Cardiac arrhythmias (including conduction disorders, atrial and ventricular arrhythmias), Cardiac ischemic conditions (including myocardial ischemia, myocardial infarction [including acute], coronary artery spasm and unstable or stable angina pectoris), Stroke / Cerebrovascular accident (CVA) and Transient Ischemic Attack (TIA), System organ failures: Cardio-respiratory arrest, Cardiac failure, Cardiopulmonary failure (including pulmonary edema), Renal insufficiency / failure, Shock, Blood cell disorders (including Heparin Induced Thrombocytopenia [HIT]), Hypotension / hypertension, Infection, Nausea and vomiting, Palpitations, dizziness, and syncope, Chest pain, Fever, Pain, Death.

AP2942557-WBU Rev. B

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

YESNO